| Date Filed | Type | Description |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/27/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/28/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
SC 13D/A
| Dudley Robert Michael reports a 6% stake in TransCode Therapeutics, Inc. |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...|
Docs:
|
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between TransCode Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purcha...",
"TransCode Therapeutics Announces Pricing of $7 Million Public Offering BOSTON, June 6, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its public offering of an aggregate of 2,000,000 shares of its common stock , together with accompanying common stock warrants, at a public offering price of $3.50 per share and accompanying warrants. Each share of common stock is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants will be exercisable immediately and will expire..." |
|
| 06/07/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 06/07/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/05/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/19/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/18/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/10/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/31/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 02/01/2023 |
8-K
| Quarterly results |
| 12/19/2022 |
SC 13D
| Dudley Robert Michael reports a 12.7% stake in TransCode Therapeutics, Inc. |
| 12/19/2022 |
SC 13G
| Medarova Zdravka reports a 12.5% stake in TransCode Therapeutics, Inc. |
| 12/19/2022 |
SC 13G
| Dudley Robert Michael reports a 10.6% stake in TransCode Therapeutics, Inc. |
| 12/19/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/13/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/09/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/06/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 11/30/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 11/30/2022 |
8-K
| Quarterly results |
|